Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193648 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CYP2D6KDM4EKMT2AMME | |
| SCHEMBL12869546 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP2D6KDM4EKMT2AMME | |
| SCHEMBL12870586 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL12258804 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CYP2D6KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL21844029 | 0.78 | MME (0.34) | MMESMN1; SMN2 | |
| SCHEMBL23513623 | 0.78 | MME (0.33) | MME | |
| SCHEMBL21083984 | 0.72 | KMT2A (0.37) | ALDH1A1CYP2D6KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL13448658 | 0.72 | KDM4E (0.65) | ALDH1A1CYP2D6KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL7876466 | 0.71 | ALDH1A1 (0.46) | ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL5240027 | 0.71 | KDM4E (0.63) | ALDH1A1CYP2D6KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590076-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590076-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | ALDH1A1 3850/4885CYP2D6 4268/4885KDM4E 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.